Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026)
Stoke Therapeutics' (STOK) quarterly Capital Expenditures came in at $353000.0 in Q1 2026, up 1207.41% year-on-year from $27000.0 in Q1 2025, and down 38.93% quarter-over-quarter from $578000.0 in Q4 2025.
Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $353000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 1207.41% year-over-year to $353000.0 in Q1 2026; TTM through Mar 2026 was $996000.0, a 344.64% increase from a year earlier, with the FY2025 full-year figure at $670000.0, up 230.05% from the prior year.
- Capital Expenditures eased to $353000.0 in Q1 2026 per STOK's latest filing, from $578000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $841000.0 in Q1 2022 and bottomed at -$348000.0 in Q3 2022.
- The 5-year median for Capital Expenditures is $52000.0 (2024), against an average of $174294.1.
- Across the five-year window, Capital Expenditures slumped 227.47% in 2022 and soared 1207.41% in 2026, its largest moves.
- Year by year, Capital Expenditures stood at -$285000.0 in 2022, then jumped by 180.35% to $229000.0 in 2023, then retreated by 16.16% to $192000.0 in 2024, then jumped by 201.04% to $578000.0 in 2025, then plunged by 38.93% to $353000.0 in 2026.
- Per Business Quant, the three latest STOK Capital Expenditures figures stand at $353000.0 (Q1 2026), $578000.0 (Q4 2025), and $41000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | 353,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 353,000.00 |
| Mar 31, 2026 | 353,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Dec 31, 2025 | 578,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 24,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Dec 31, 2024 | 192,000.00 |
| Sep 30, 2024 | -47,000.00 |
| Sep 30, 2024 | -47,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 229,000.00 |
| Dec 31, 2023 | 229,000.00 |